Seoul–(Newswire)–This study was published in the “Journal of Medical Virology (IF=12.7)” published by the American publisher Wiley. It is a renowned international academic journal ranked second in the world in the field of virology.
Search scheme. Professor Choi In-soo’s team from Konkuk University has confirmed the safety and antiviral effect of a recombinant adenovirus expressing the interferon lambda protein against the influenza virus.
※ 논문명: Antiviral activity of the adenoviral vector expressing human interferon lambda-4 against influenza virus
In this study, a system was developed to deliver the interferon lambda gene, which exhibits antiviral efficacy, via recombinant adenovirus.
Interferon lambda is a protein that is expressed as an innate immune response when foreign pathogenic substances such as viruses invade the body and exerts an antiviral effect. Unlike interferon type 1 (interferon alpha, etc.), which is currently used as a treatment for viruses, interferon type 3 (interferon lambda) has a low risk of side effects such as inflammation and fever in the body, so This is why clinical trials are being conducted around the world. It’s a protein that exists.
To develop a treatment for human influenza, the research team inserted the human interferon gene lambda-4 into the gene of a recombinant adenovirus. In order to use the treatment as a medicine, experiments were also conducted to apply for clinical trial (IND) approval.
Treatment with recombinant adenovirus was confirmed by immunostaining and electron microscopy and was approved by the Ethics Committee for Animal Experiments and the Biological Safety Committee for the evaluation of safety and efficacy in cells and experimental animals.
Subsequently, the safety of the drug was evaluated according to Good Clinical Practice (GLP) and the effectiveness of the treatment for highly pathogenic influenza was also evaluated using a biosafety level 3 (BL3) facility established at the University of Konkuk. The BL3 facility is a special facility for the safe management of high biohazard pathogens. Konkuk University received national certification in 2009 and manages it by exceeding tough and rigorous standards for high-risk pathogen research every year.
Research results showed that recombinant adenovirus expressing human interferon lambda-4 protein enhanced the expression of innate immune system genes in cells and mice, thereby inhibiting the proliferation of two types of low pathogenic influenza viruses and two types of highly pathogenic influenza viruses. The human interferon lambda protein was more effective in human-derived cells than in mouse ones, but the amount of infectious virus was significantly reduced in the mice’s lungs, and the degree of inflammation was confirmed to be lower when I could confirm it histologically.
This research was supported by the Technology Development Project for the Prevention and Treatment of Infectious Diseases of the Ministry of Health and Welfare and the Excellent Research Human Resources Training Project of Konkuk University, and the paper was also introduced in “The People Who Make Korea Shine” from the Biological Research Information Center (BRIC).
Website:
#Professor #Choi #Insoos #team #Konkuk #University #published #article #development #influenza #treatment #interferon #worldclass #academic #journal
